Celcuity is a commercial-stage biotechnology company focused on advancing targeted therapies for cancers driven by the PAM (PI3K/AKT/mTOR) pathway
Celcuity is a commercial-stage biotechnology company focused on advancing targeted therapies for cancers driven by the PAM (PI3K/AKT/mTOR) pathway. Their first approved product, REVTORPYK (gedatolisib), targets all Class I isoforms of PI3K and mTOR complexes to block the PAM pathway comprehensively.